Fredun Pharmaceuticals Ltd — Important, 12-06-2026: Company Update

Fredun Pharmaceuticals reported strong Q4 and FY26 results. Q4 total income grew 27.27% to 213 Cr, EBITDA rose 67.05% to 29.13 Cr, and net profit surged 56.47% to 11.07 Cr. For the full year, total income hit 639.12 Cr, up 40.08%, with EBITDA at 94.79 Cr (up 72.05%) and net profit at 33.21 Cr (up 59.59%). The company is launching high-margin hormonal and anti-aging product lines. Its Mobility division aims for 100 Cr in 2-2.5 years, and the Pet Care business, including the Wagr.in platform, is expanding with unique offerings. Management anticipates continued robust growth with improving margins and cash flows.